Bicyclol Attenuates Acute Liver Injury by Activating Autophagy, Anti-Oxidative and Anti-Inflammatory Capabilities in Mice
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Bicyclol, a novel synthetic antihepatitis drug, has been shown to protect against liver injury via various pharmacological activities. The purpose of the current study was to further investigate the protective effect of bicyclol against carbon tetrachloride (CCl4)-induced acute liver injury (ALI) and its underlying molecular mechanism, particularly autophagic machinery, anti-oxidative and anti-inflammatory potentials. Our results found that treatment with bicyclol significantly reduced CCl4-induced hepatotoxicity by alleviating histopathological liver changes, decreasing the alanine transaminase levels, promoting autophagic flux, attenuating the expression of inflammatory cytokines and modulating oxidative markers. Furthermore, bicyclol efficiently induced the conversion of LC3 and enhanced the liver expressions of ATG7 and Beclin-1. Meanwhile, bicyclol induced the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and p62. These protective effects may be mediated by activation of AMP-activated protein kinase and inhibition of mTOR or MAPK signaling pathways. Taken together, our study firstly suggests that bicyclol has protective potential against CCl4-induced hepatotoxicity, which might be closely associated with induction of autophagy, concomitant anti-oxidative stress and anti-inflammatory response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Self-consumption: the interplay of autophagy and apoptosis
Mariño, G., Niso-Santano, M., Baehrecke, E. H., & Kroemer, G. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3735 · Cited by 2,172
Autophagy-deficient mice develop multiple liver tumors
Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., Eishi, Y., Hino, O., Tanaka, K., & Mizushima, N. (2011) · Genes & Development · doi:10.1101/gad.2016211 · Cited by 1,342 · cited 1×
“However, p62 accumulation with aggregates of ubiquitylated proteins, under the condition of disrupted autophagy, can result in various pathological consequences including liver diseases (Rusten and Stenmark, 2010; Takamura et al., 2011).”
BackgroundItakura, E., & Mizushima, N. (2010) · Autophagy · doi:10.4161/auto.6.6.12709 · Cited by 843 · cited 2×
“Specially, ATG7 is a key factor in the ubiquitin-like pathway of LC3 lipidation, while Beclin-1 interacts with VPS34, HMGB1 and Rubicon for modulating the autophagy process (Itakura and Mizushima, 2010; Shi et al., 2017).”
BackgroundAutophagy in the liver: functions in health and disease
Ueno, T., & Komatsu, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.185 · Cited by 500
Update of the NAD(P)H:Quinone oxidoreductase (NQO) gene family
Vasiliou, V., Ross, D., & Nebert, D. W. (2006) · Human Genomics · doi:10.1186/1479-7364-2-5-329 · Cited by 178
Cited by
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Tang, J., Gu, J., Chu, N., Chen, Y., Wang, Y., Xue, D., Xie, Q., Li, L., Mei, Z., Wang, X., et al. (2022) · Liver International · doi:10.1111/liv.15290 · Cited by 25
Self-citationLi, H., Liu, N.-N., Li, J.-R., Wang, M.-X., Tan, J.-L., Dong, B., Lan, P., Zhao, L.-M., Peng, Z.-G., & Jiang, J.-D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113083 · Cited by 20
Metadata
- Authors
- Zhao, T.-M., Wang, Y., Deng, Y., Fan, X.-F., Cao, X.-C., Hou, L.-J., Mao, L.-H., Lin, L., Zhao, W., Wang, B.-M., Jiang, K., Zhao, J.-W., & Sun, C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-17
- Volume
- 11
- Pages
- 463-463
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3016431343
- Cited by
- 35
- References
- 5
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.